Articles by Zachary Bessette
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
The prevalence, outcomes of patients with HRR mutations who initiated 1L mCRPC treatment with a novel hormonal therapy.
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Dr. Rini provided an overview of nccRCC, including data pertaining to response to IO monotherapy and IO/TKI combinations.
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
The results of a new systematic review showed the evidence base regarding ICIs as adjuvant therapy in RCC is “mixed.”
Dr. Neal Shore presented the results of the phase 3 randomized EMBARK study as a late-breaking abstract.
New research highlights real-world outcomes of targeted therapy and immunotherapy for patients with metastatic pRCC.
Comparing outcomes of patients receiving consolidative nephrectomy after systemic immunotherapy vs cytoreductive surgery.
During an afternoon plenary session, Dr. Jonathan Coleman presented the updates to the AUA guideline for UTUC.
Active surveillance is not inferior to intervention for small renal masses suspicious for RCC, according to new research.
IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC.
Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial.
A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.
670 Madison Ave.
Manalapan, NJ 07726